daunorubicin has been researched along with Refractory Anemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Arimori, S; Nagao, T; Yonekura, S | 1 |
2 other study(ies) available for daunorubicin and Refractory Anemia
| Article | Year |
|---|---|
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia.
Topics: Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid; Male; Mercaptopurine; Prednisolone; Thrombocythemia, Essential | 1992 |